Stockholder Information


Common Stock

Ticker symbol: BMY New York Stock Exchange

Annual Meeting of Stockholders

Tuesday, May 1, 2018 10:00 a.m. Bristol-Myers Squibb Company 3401 Princeton Pike Lawrence Township, NJ 08648

Stockholder Services

All inquiries concerning stockholder accounts and stock transfer matters – including address changes, the elimination of duplicate mailings and the Shareowner Services Plus PlanSM – should be directed to the Company’s Transfer Agent and Registrar:
EQ Shareowner Services 1110 Centre Pointe Curve, Suite 101 Mendota Heights, MN 55120-4100 855-598-5485 (within the U.S.) 651-450-4064 (outside the U.S.) A telecommunications relay service should be used by the hearing impaired when calling the telephone numbers above.

Shareowner Services Plus PlanSM

The Shareowner Services Plus PlanSM is designed for long-term investors who wish to build share ownership in the Company’s common stock over time. You can participate in the plan if you are a registered holder of the Company’s common stock. If you do not own the Company’s common stock, you can become a participant by making your initial purchase through the plan. The plan features dividend reinvestment, optional cash purchase, share safekeeping, and share sales and transfers. Bristol-Myers Squibb Company has appointed EQ Shareowner Services as Administrator for the plan. The plan is not sponsored or administered by Bristol-Myers Squibb Company.

Form 10-K

For a free copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, contact: Corporate Secretary Bristol-Myers Squibb Company 345 Park Avenue New York, NY 10154-0037
New address effective July 1, 2018:
430 E. 29 Street, 14FL New York, NY 10016 The Form 10-K is also available at
The most recent certifications by the Company’s chief executive officer and chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to the Company’s Form 10-K. The Company has also filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual.Additional Information

Additional Information

Information on the following subjects is available at
  • Bristol-Myers Squibb Foundation
  • Clinical Trials
  • Compliance and Ethics
  • Diversity and Workforce Statistics
  • Patient Assistance Programs
  • Policy and Advocacy Engagement and Political Contributions
  • Sustainability/Environmental Programs
This Annual Report contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. Please see page 28 in the Financial Review for a discussion and description of these risks and uncertainties. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Product Names and Company Programs

Global products and company program names appearing throughout in italics are referred to herein by their registered and approved U.S. trademarks, unless specifically noted otherwise.

Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.

Adcetris is a trademark of Seattle Genetics, Inc.

Atripla is a trademark of Bristol-Myers Squibb and Gilead Sciences, LLC

Avapro/Avalide (known in the EU as Aprovel/Karvea) and Plavix are trademarks of Sanofi

Bydureon, Byetta and Symlin are trademarks of Amylin Pharmaceuticals, LLC

Cabometyx is a trademark of Exelixis, Inc.

ENHANZE is a trademark of Halozyme, Inc.

Erbitux is a trademark of ImClone LLC

Farxiga and Onglyza are trademarks of AstraZeneca AB

Gleevec is a trademark of Novartis AG

Ixempra is a trademark of R-Pharm US Operating, LLC

Keytruda is a trademark of Merck Sharp & Dohme Corp.

Myalept is a trademark of Aegerion Pharmaceuticals, Inc.

Prostvac is a trademark of BN ImmunoTherapeutics Inc.

Recothrom is a trademark of The Medicines Company

Rubraca is a trademark of Clovis Oncology, Inc.

Truvada and Tybost are trademarks of Gilead Sciences, Inc. and/or one of its affiliates.

Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of Bristol-Myers Squibb and/or one of its subsidiaries.

Shareowner Services Plus Plan is a Service Mark of EQ Shareowner Services
Details 01/15/2017